Drug intelligence / Profile preview

Codispaq

Development stage: Preclinical
Lead developer: Landcent
Modality: Small Molecules
Administration: Oral

Overview

Codispaq (also known as Lansipar) is a long-acting antimalarial preventive medication developed by Landcent. It is designed as a public health product and commodity to prevent malaria in vulnerable populations, specifically children and pregnant women in endemic regions such as Sub-Saharan Africa. Positioned as a public health commodity rather than a traditional clinical-stage pharmaceutical candidate, Codispaq does not have associated molecular targets or clinical trial phases in standard registries, but is part of Landcent's portfolio of malaria prevention solutions.

Brand names: CodispaqLansipar

Beyond the preview

Go deeper on Codispaq.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Codispaq.

Explore the full profile